Borealis Biosciences is a Canadian biotechnology company focused on developing next-generation RNA-based medicines for kidney diseases. The company leverages xRNA technology, which targets the body's natural mRNA to modulate protein production linked to disease. Borealis is backed by Novartis and Versant Ventures and has a strategic research collaboration with Novartis.

Borealis Biosciences

Director, Research Engineering

Molecular Biology and Genomics Contractor

Research Associate I, Translational Biology & Pharmacology

Animal Care Contractor


                Lead Histology Technician
              


              Scientist, Oligonucleotide Chemistry
            


              Sr. Research Associate, Oligonucleotide Chemistry
            

Biotech is Buzzing in Vancouver as 2024 Marks Year of Momentum for the Sector - Techcouver.com


                Scientist II, Discovery Biology
              


                Senior Accountant
              

Borealis Biosciences: RNA Medicines Company Secures $30 Million (Series A Extension) - Pulse 2.0

Borealis Biosciences Raises Additional $30M in Series A Financing - FinSMEs

Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding - Yahoo Finance

Versant Ventures and Novartis Launch Borealis Biosciences With $150 Million in Funding

Daiichi Sankyo finds successor to late R&D exec; Versant, Novartis' kidney biotech poaches Sana CBO - Endpoints News

Raising awareness and funds for a vital cause! The Borealis Bio team stepped out on June 1st for the 2025 Kidney Walk, a province-wide event supporting the kidney and transplant communities. Kidney disease affects so many, and these walks play a critical role in providing hope and resources. We're committed to making a difference. #KidneyWalkCanada @KidneyBCY

Q3’24 Venture Pulse Report - Americas - KPMG

Borealis Bio emerges from stealth with Versant and Novartis funding - The Pharma Letter


                Research Associate I, Biology
              

Novartis and Versant Partner to Form Kidney Disease Biotech - Contract Pharma

Borealis Biosciences, Inc. announced that it has received CAD 245.0644 million in funding from Versant Venture Management, LLC, Novartis AG, Westlake Village BioPartners - Marketscreener.com

Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing - Business Wire

Daily Times Chronicle Events - 7th CKD3 Summit 2025 - Homenewshere.com


              Scientist, Bioconjugation Chemistry
            

March is National Kidney Month, an important time to raise awareness about kidney disease. At Borealis, our focus is on developing medicines that will ultimately save lives and decrease the need for kidney transplants.  As of today, however, transplant remains the only option for many patients.

Borealis is a proud member of the American Society of Transplantation's Living Donor Circle of Excellence program, with support from strategic partner the National Kidney Foundation. The program recognizes companies that have policies in place to support the wages of employees who become living donors.  We are pleased to offer this benefit to our employees.

Why is this important?

- Critical Need: Over 100,000 patients are currently waiting for life-saving kidney or liver transplants.
- Living Donors Make a Difference: In 2021, living donors accounted for 24% of kidney transplants.
- Removing Barriers: Financial concerns often deter potential living donors. The typical recovery period of four to six weeks can force individuals to use vacation time or take unpaid leave.

Learn more about the Living Donor Circle of Excellence at LivingDonorCircle.com


                Scientist, Translational Biology & Pharmacology
              

Versant’s Jerel Davis on build-to-buy deals and pharma investment - BioPharma Dive


                Research Associate, Translational Biology & Pharmacology
              

Novartis and Versant launch Borealis with $150m funding - Pharmaceutical Technology

Vancouver Biotech Startup Emerges from Stealth with $150M to Combat Kidney Disease - Techcouver.com

Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing

The biggest private biotech investments in August 2024 - Labiotech.eu

We’re excited to welcome Christian Hordo as our new CEO, along with a $30 million infusion from an extension of the Series A led by Westlake BioPartners and the addition of three new board directors, David Allison, Tom Frohlich and Catherine Thut.
 
With the Series A expansion, the company now has $180 million of capital to develop next-generation RNA medicines for kidney disease.  
 
Learn more at https://lnkd.in/gVA-2x7y

#biotech #RNA #kidneydisease

Novartis and Versant launch Borealis Biosciences with $150m - Yahoo Finance

Wilson Sonsini Advises Borealis Biosciences on $150 Million Series A and Strategic Collaboration Funding - Wilson Sonsini


              Protein Scientist, Biology
            

Novartis and Versant to form biotech venture Borealis Biosciences - Indian Pharma Post

Novartis, Versant Form New Biotech Company Focused on Kidney Diseases - Docwire News

Borealis Biosciences Raises $150M in Series A Funding - FinSMEs

Borealis Biosciences

Business:

About: